RCKT

Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

Rocket Pharmaceuticals, Inc. (RCKT) is rated C+ (2.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (A+); its weakest is Momentum (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.8 / 5.0
C+
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
D+
Factor Score 1.8 / 5.0
Revisions
A+
Factor Score 5.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.4
EV / EBITDA -0.3
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -32.4%
Price Return 12M -30.3%
Catalyst Signal 0.00
Market Cap $252.5M
TTM Revenue N/A
Price / Sales N/A
ROE -5.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C+ (2.5) C+ (2.5) C- (2.1) D+ (1.8) A+ (5.0) C+ (2.8)
2026-11-07 C+ (2.5) C+ (2.5) C+ (2.7) D+ (1.8) A+ (5.0) B- (2.9)
2026-10-31 C+ (2.5) C+ (2.5) C+ (2.7) D+ (1.8) A+ (5.0) B- (2.9)
2026-10-24 B+ (3.7) C+ (2.5) C+ (2.7) D+ (1.7) A+ (5.0) B- (3.1)
2026-10-17 B+ (3.7) C+ (2.5) C+ (2.7) C- (1.9) A+ (5.0) B (3.2)
Page 1 of 4